Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein

Abstract Erdheim-Chester disease is a rare non-langerhans systemic histiocytosis of unknown origin, associated with bone diseases and severe visceral complications. Therapies have been disappointing. A recombinant form of interleukin-1 receptor antagonist (anakinra) has been used in a few cases when...

Full description

Saved in:
Bibliographic Details
Published in:Joint, bone, spine : revue du rhumatisme bone, spine : revue du rhumatisme, 2014-03, Vol.81 (2), p.175-177
Main Authors: Courcoul, Audrey, Vignot, Emmanuelle, Chapurlat, Roland
Format: Article
Language:English
Subjects:
Anakinra
Antirheumatic Agents - therapeutic use
Erdheim-Chester disease
Erdheim-Chester Disease - drug therapy
Histiocytosis
Humans
Interleukin 1 Receptor Antagonist Protein - therapeutic use
Interleukin-1 receptor antagonist protein
Internal Medicine
Male
Middle Aged
Rheumatology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Erdheim-Chester disease is a rare non-langerhans systemic histiocytosis of unknown origin, associated with bone diseases and severe visceral complications. Therapies have been disappointing. A recombinant form of interleukin-1 receptor antagonist (anakinra) has been used in a few cases when usual treatment fails. We report a new case of successfully interleukin-1 receptor antagonist treatment in Erdheim-Chester disease.
ISSN:1297-319X
1778-7254
DOI:10.1016/j.jbspin.2013.06.013